Novartis Opts For OTC Recall, With J&J/McNeil Lessons Still Fresh
This article was originally published in The Tan Sheet
Executive Summary
After shuttering its Lincoln, Neb., OTC facility, the firm recalls some lots of Bufferin, Excedrin, Gas-X and NoDoz. FDA found a “pattern of problems” when inspecting the plant in 2011, and Novartis’ actions suggest it seeks to avoid the same scrutiny that Johnson & Johnson’s OTC recalls elicited.
You may also be interested in...
In Brief
Shareholder suit against Johnson & Johnson, including CFO Caruso, may proceed; Novartis pauses OTC production at Nebraska plant; Mead Johnson finds Enfamil powder clear of bacteria after stores pull the product; John Gay leaves NPA after two years as executive director and CEO; more news In Brief.
Perrigo Applies Crime Scene Investigation Model To Improve Quality Control
Perrigo quality control managers emphasize immediate investigations of low-risk incidents and forward-looking remediation in the firm’s new corrective and preventive actions strategy.
Perrigo To Launch Private Label Mucinex, Prevacid, With An Eye On Lipitor
Private label giant Perrigo is readying generic competitors to Reckitt Benckiser’s Mucinex and Takeda Pharmaceuticals’ Prevacid, CEO Joseph Papa says.